This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00258375
Recruitment Status : Completed
First Posted : November 24, 2005
Last Update Posted : August 4, 2023
Information provided by (Responsible Party):
Canadian Cancer Trials Group ( NCIC Clinical Trials Group )

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. OGX-011 may help docetaxel kill more tumor cells by making tumor cells more sensitive to the drug.

PURPOSE: This phase II trial is studying how well giving OGX-011 together with docetaxel works in treating women with locally advanced or metastatic breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: custirsen sodium Drug: docetaxel Phase 2

Detailed Description:



  • Determine the efficacy of OGX-011 and docetaxel, in terms of objective tumor response rate, in women with locally advanced or metastatic breast cancer.


  • Determine the tolerability and toxicity of this regimen in these patients.
  • Determine the time to progression and overall survival of patients treated with this regimen.

OUTLINE: This is an open-label, nonrandomized, multicenter study.

Patients receive OGX-011 IV over 2 hours on days -7, -5, -3, 1, 8, and 15 of course 1 and on days 1, 8, and 15 of all subsequent courses. Patients also receive docetaxel IV over 1 hour on days 1 and 8 of all courses. Treatment repeats every 21 days* for up to 10 courses in the absence of disease progression or unacceptable toxicity.

NOTE: *Course 1 is 28 days in length and all subsequent courses (courses 2-10) are 21 days in length.

After completion of study treatment, patients are followed at 4 weeks and then periodically until disease progression.

PROJECTED ACCRUAL: Approximately 42 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination With Docetaxel in Advanced Breast Cancer
Actual Study Start Date : October 21, 2005
Actual Primary Completion Date : February 23, 2007
Actual Study Completion Date : September 22, 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Docetaxel

Primary Outcome Measures :
  1. Objective response measured by RECIST criteria after accrual of 14 evaluable patients

Secondary Outcome Measures :
  1. Toxicity

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 120 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Histologically confirmed breast cancer

    • Metastatic or locally advanced disease
    • Not curable with standard therapy
  • Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan

    • Lesion must be outside of the previously irradiated field

      • If the sole site of disease is in a previously irradiated field, there must be evidence of disease progression or new lesions in the irradiated field
  • No known CNS metastases
  • Hormone receptor status:

    • Not specified



  • Female

Menopausal status

  • Not specified

Performance status

  • ECOG 0-2

Life expectancy

  • At least 12 weeks


  • Platelet count ≥ 100,000/mm^3
  • Absolute granulocyte count ≥ 1,500/mm^3
  • PTT, PT, and INR normal
  • No known bleeding disorder


  • Bilirubin normal
  • AST and ALT ≤ 1.5 times upper limit of normal (ULN)


  • Creatinine ≤ 1.5 times ULN


  • No significant cardiac dysfunction


  • No active uncontrolled infection
  • No history of serious allergic reaction to taxanes, including paclitaxel or docetaxel


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No preexisting neuropathy ≥ grade 2
  • No other malignancies within the past 5 years except adequately treated nonmelanoma skin cancer or curatively treated carcinoma in situ of the cervix
  • No other serious medical condition or illness that would preclude study participation
  • No significant neurological disorder that would preclude giving informed consent


Biologic therapy

  • Prior trastuzumab (Herceptin^®) allowed


  • Recovered from prior chemotherapy
  • At least 6 months since prior adjuvant chemotherapy (taxanes allowed)
  • At least 4 weeks since prior chemotherapy for advanced disease

    • No prior taxanes for advanced disease
  • No more than 1 prior chemotherapy regimen for advanced disease
  • No other concurrent chemotherapy

Endocrine therapy

  • At least 1 week since prior hormonal therapy


  • See Disease Characteristics
  • At least 4 weeks since prior radiotherapy

    • Low-dose, nonmyelosuppressive radiotherapy allowed within 4 weeks before study entry at the discretion of the investigator
  • No prior radiotherapy ≥ 30% of functioning bone marrow
  • No concurrent radiotherapy


  • At least 3 weeks since prior major surgery and recovered (wound healing must have occurred)


  • More than 4 weeks since prior investigational agents or new anticancer therapy
  • No concurrent therapeutic anticoagulation therapy except low-dose oral anticoagulant therapy (i.e., 1 mg of oral warfarin once a day) or low molecular weight heparin
  • No other concurrent investigational therapy
  • No other concurrent cytotoxic therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00258375

Layout table for location information
Canada, British Columbia
British Columbia Cancer Agency - Centre for the Southern Interior
Kelowna, British Columbia, Canada, V1Y 5L3
BCCA - Fraser Valley Cancer Centre
Surrey, British Columbia, Canada, V3V 1Z2
British Columbia Cancer Agency - Vancouver Cancer Centre
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Ontario
London Regional Cancer Program at London Health Sciences Centre
London, Ontario, Canada, N6A 4L6
Ottawa Hospital Regional Cancer Centre - General Campus
Ottawa, Ontario, Canada, K1H 8L6
Sponsors and Collaborators
NCIC Clinical Trials Group
Layout table for investigator information
Study Chair: Stephen Chia, MD British Columbia Cancer Agency
Publications of Results:
Chia S, Dent S, Ellard SL, et al.: A phase II trial of a second generation antisense oligonucleotide (ASO) to clusterin (OGX-011) in combination with docetaxel in metastatic breast cancer (MBC): NCIC-CTG IND 164 trial. [Abstract] American Association for Cancer Research: 98th Annual Meeting, April 14-18, 2007, Los Angeles, CA. A-3512, 2007.

Layout table for additonal information
Responsible Party: NCIC Clinical Trials Group Identifier: NCT00258375    
Other Study ID Numbers: I164
CAN-NCIC-IND164 ( Other Identifier: PDQ )
ONCOGENEX-OGX-011-06 ( Other Identifier: Oncogenex Technologies )
CDR0000450847 ( Other Identifier: PDQ )
First Posted: November 24, 2005    Key Record Dates
Last Update Posted: August 4, 2023
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Canadian Cancer Trials Group ( NCIC Clinical Trials Group ):
stage IIIA breast cancer
stage IIIB breast cancer
stage IIIC breast cancer
stage IV breast cancer
recurrent breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action